VTYX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Ventyx Biosciences's net margin of 21.68%. Ventyx Biosciences's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Ventyx Biosciences has a consensus price target of $12.00, signalling upside risk potential of 283.39%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Ventyx Biosciences has higher upside potential than Eli Lilly and, analysts believe Ventyx Biosciences is more attractive than Eli Lilly and.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ventyx Biosciences quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Ventyx Biosciences's net income of -$27.4M is lower than Eli Lilly and's net income of $2.8B. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -- compared to Ventyx Biosciences's net margin of 26.7%. Ventyx Biosciences's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Ventyx Biosciences has a consensus price target of $12.00, signalling upside risk potential of 283.39%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $728.55 which suggests that it could grow by 32.96%. Given that Ventyx Biosciences has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ventyx Biosciences is more attractive than Regeneron Pharmaceuticals.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.325, suggesting its less volatile than the S&P 500 by 67.458%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.32% to investors and pays a quarterly dividend of $0.88 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Ventyx Biosciences's net income of -$27.4M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus 4.44x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Verve Therapeutics has a net margin of -- compared to Ventyx Biosciences's net margin of -94.11%. Ventyx Biosciences's return on equity of -- beat Verve Therapeutics's return on equity of -34.75%.

Ventyx Biosciences has a consensus price target of $12.00, signalling upside risk potential of 283.39%. On the other hand Verve Therapeutics has an analysts' consensus of $15.11 which suggests that it could grow by 37.09%. Given that Ventyx Biosciences has higher upside potential than Verve Therapeutics, analysts believe Ventyx Biosciences is more attractive than Verve Therapeutics.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Verve Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verve Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Verve Therapeutics pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than Verve Therapeutics quarterly revenues of $33M. Ventyx Biosciences's net income of -$27.4M is higher than Verve Therapeutics's net income of -$31M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Verve Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus 16.01x for Verve Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Ventyx Biosciences's net margin of --. Ventyx Biosciences's return on equity of -- beat Viking Therapeutics's return on equity of --.

Ventyx Biosciences has a consensus price target of $12.00, signalling upside risk potential of 283.39%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 185.37%. Given that Ventyx Biosciences has higher upside potential than Viking Therapeutics, analysts believe Ventyx Biosciences is more attractive than Viking Therapeutics.

Ventyx Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.623, suggesting its less volatile than the S&P 500 by 37.744%.

Ventyx Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ventyx Biosciences pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Ventyx Biosciences quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Ventyx Biosciences's net income of -$27.4M is higher than Viking Therapeutics's net income of -$45.6M. Notably, Ventyx Biosciences's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ventyx Biosciences is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.